News

NIH R01 grant awarded!

The McFarland group has been awarded an R01 grant from the National Institutes of Health / National Cancer Institute. This funding will…

John presents at the ACS Poster Night

John Roque presented his results with photoejecting compounds at the ACS Poster Vendor Night hosted at Syngenta in Greensboro.

Lex presents at the UNCG Chemistry and Biochemistry Undergraduate Research Symposium

Lex (Katsuya Colon) presented at the UNCG Chemistry and Biochemistry Undergraduate Research Symposium, one of four students chosen to highlight their contributions…

Derick appears in C&EN

Our Ph.D. student Derick Jones represented the group at this year’s NOBCChE conference. His photo appeared in C&EN! (C&EN Volume 95 Issue…

Improvement by ten orders of magnitude

A press release from our partner company reports that our newest generation of cancer-fighting drugs is ten billion times more potent than…

Katsuya “Lex” Colon wins an award

Lex’s excellence in the research lab was recognized with the awarding of the Lilian Nile Undergraduate Research Assistantship at the 2017 Homecoming….

Preclinical news: destroying brain cancer!

In preclinical results, our lead cancer drug, TLD-1433, has been shown to destroy the human brain cancer glioblastoma multiforme (GBM) when activated…

Our research article made the cover of Photochemistry and Photobiology!

Our article Novel Osmium-based Coordination Complexes as Photosensitizers for Panchromatic Photodynamic Therapy is the feature article in the journal Photochemistry and Photobiology….

Independent validation of our cancer drugs

A recent publication in Inorganic Chemistry uses computational tools to validate the TypeI/TypeII dual mode activity in our cancer drugs. See our…

Second patent granted for Ruthenium-based PDT cancer drugs

A second patent (US #9,676,806) has been granted for our high-potency photodynamic cancer drugs.